Drugs / LivaloVA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05351840 | Nov → Dec 2020 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05331014 | Nov 2021 → Nov 2022 | hyperlipidemia, hypertensive disorder | JW Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LivaloVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05331014 ↗ |
| Route | Oral | “then take it by oral” NCT05351840 ↗ |